Prognostic value of lipopolysaccharide binding protein and procalcitonin in patients with severe sepsis and septic shock admitted to intensive care;Valor pronóstico de la proteína fijadora de lipopolisácaridos y la procalcitonina en pacientes con sepsis grave y shock séptico ingresados en una unidad de cuidados intensivos

Medicina Intensiva

Volumn 39, Issue 4, 2015, Pages 207-212

  Garcia de Guadiana Romualdo L M ^a   Rebollo Acebes, S ^a   Esteban Torrella, P ^a   Jimenez Sanchez R ^a   Hernando Holgado, A ^a   Ortin Freire A ^a   Viqueira Gonzalez M ^a   Trujillo Santos, J ^a   Jimenez Santos E ^a   Pedregosa Diaz J ^a   Albaladejo Oton M D ^a   Allegue Gallego, J M ^a  

^a HOSPITAL UNIVERSITARIO SANTA LUCÍA   (Spain)

Author keywords

In hospital mortality; Lipopolysaccharide binding protein; Procalcitonin; Prognosis; Sepsis

Indexed keywords

LIPOPOLYSACCHARIDE BINDING PROTEIN; PROCALCITONIN; ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; CALCITONIN; CARRIER PROTEIN; LIPOPOLYSACCHARIDE-BINDING PROTEIN; MEMBRANE PROTEIN;

ARTICLE; DISEASE SEVERITY; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MORTALITY; OBSERVATIONAL STUDY; PROGNOSIS; PROSPECTIVE STUDY; SEPTIC SHOCK; SURVIVAL; UNIVERSITY HOSPITAL; AGED; APACHE; AREA UNDER THE CURVE; BLOOD; EPIDEMIOLOGY; FEMALE; HOSPITAL MORTALITY; INTENSIVE CARE UNIT; MALE; MIDDLE AGED; ORGAN DYSFUNCTION SCORE; RECEIVER OPERATING CHARACTERISTIC; SEPSIS; SPAIN; STATISTICS AND NUMERICAL DATA;

ACUTE-PHASE PROTEINS; AGED; APACHE; AREA UNDER CURVE; BIOMARKERS; CALCITONIN; CARRIER PROTEINS; FEMALE; HOSPITAL MORTALITY; HOSPITALS, UNIVERSITY; HUMANS; INTENSIVE CARE UNITS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; ORGAN DYSFUNCTION SCORES; PATIENT ADMISSION; PROGNOSIS; ROC CURVE; SEPSIS; SHOCK, SEPTIC; SPAIN;

EID: 84928204195     PISSN: 02105691     EISSN: 15786749     Source Type: Journal    
DOI: 10.1016/j.medin.2014.04.005     Document Type: Article

References (26)

1. Angus D.C., Linde-Zwirble W.T., Lidicker J., Clermont G., Carcillo J., Pinsky M.R. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated cost of care. Crit Care Med. 2001, 29:1303-1310.
2. Esteban A., Frutos-Vivar F., Ferguson N.D., Peñuelas O., Lorente J.A., Gordo F., et al. Sepsis incidence and outcome: Contrasting the intensive care unit with the hospital ward. Crit Care Med. 2007, 35:1284-1289.
3. Vincent J.L., Donadello K., Schmit X. Biomarkers in the critically ill patient: C-reactive protein. Crit Care Clin. 2011, 27:241-251.
4. Nguyen B.H., Rivers E.P., Knoblich B.P., Jacobsen G., Muzzin A., Ressler J., et al. Early lactate clearance is associated with improved outcome in severe sepsis and septic shock. Crit Care Med. 2004, 32:1637-1642.
5. Riedel S. Procalcitonin and the role of biomarkers in the diagnosis and management of sepsis. Diagn Microbiol Infect Dis. 2012, 73:221-227.
6. Jensen J.U., Heslet L., Ensen T.H., Espersen K., Steffensen P., Tvede M.K. Procalcitonin increase in early identification of critically ill patients with a high risk of mortality. Crit Care Med. 2006, 34:2596-2606.
7. Georgeopoulou A., Savva A., Giamarello-Bourboulis E.J., Georgitis M., Raftogiannis M., Antonakos A., et al. Early changes of procalcitonin may advise about prognosis and appropriateness of antimicrobial therapy in sepsis. J Crit Care. 2011, 26:331.e1-331.e7.
8. Karlsson S., Heikinnen M., Pettila V., Alila S., Vaisanen S., Pulkki K., et al. Predictive value of procalcitonin decrease in patients with severe sepsis: A prospective observational study. Crit Care Med. 2010, 14:R205.
9. Suberviola B., Castellanos-Ortega A., González-Castro A., García-Astudillo L.A., Fernández Miret B. Valor pronóstico del aclaramiento de procalcitonina, PCR y leucocitos en el shock séptico. Med Intensiva. 2012, 36:177-184.
10. Schuetz P., Maurer P., Punjabi V., Desai A., Amin D.N., Gluck E. Procalcitonin decrease over 72hours in US critical care units predicts fatal outcome in sepsis patients. Crit Care. 2013, 17:R115.
11. Opal S.L., Scannon P.J., Vincent J.L., White M., Carroll S.F., Palardy J.E., et al. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis. 1999, 180:1584-1589.
12. Prucha M., Herold I., Zazula R., Dubska L., Dostal M., Hildebrand T., et al. Significance of lipopolysaccharide-binding protein (an acute phase protein) in monitoring critically ill patients. Crit Care. 2003, 7:R154-R159.
13. Sakr Y., Burgett U., Nacul F.E., Reinhart K., Brunkhorst F. Lypopolysaccharide-binding protein in a surgical intensive care unit: A marker of sepsis?. Crit Care Med. 2008, 36:2014-2022.
14. Mierzchala M., Krzystek-Korpacka M., Gamian A., Durek G. Quantitative indices of dynamics in concentrations of lipopolysaccharide-binding protein (LBP) as prognostic factors in severe sepsis/septic shock patients. Comparison with CRP and procalcitonin. Clin Biochem. 2011, 44:357-363.
15. Schumann R., Zweigner J. A novel acute-phase marker: Lypopolysaccharide binding protein (LBP). Clin Chem Lab Med. 1999, 37:271-274.
16. Vreugdenhil A.C., Snoek A.M., van't Beer C. LPS-binding protein circulated in association with apo-containing lipoproteins and enhances endotoxin-LDL/VLDL interaction. J Clin Invest. 2001, 107:225-234.
17. Levy M.M., Fink M.P., Marshall J.C., Abraham E., Angus D., Cook D., et al. 2001 SCCM/ESIMC/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 2003, 29:530-538. International Sepsis Definitions Conference.
18. Carrol SF, Dedrick L, White ML. Plasma levels of lypopolisaccharide binding protein (LBP) correlate with outcome in sepsis and other patients [abstract 101]. En: Abstracts of the Sixth Vienna Shock Forum. Vienna, Austria: 8-11 November 1997.
19. León Gil C., García-Castrillo Riesgo L., Moya Mir M., Artigas Raventós A., Borges Sa M., Candel González F.J., et al. Documento de consenso (SEMES-SEMICYUC): Recomendaciones del manejo diagnóstico-terapéutico inicial y multidisciplinario de la sepsis grave en los servicios de urgencias hospitalarios. Med Intensiva. 2007, 31:375-387.
20. Schuetz P., Albrich W., Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: Past, present and future. BMC Med. 2011, 9:107.
21. Moretti D., Ramírez M.M., Settecase C.J., Bagilet D.H., Quaglino M.B. Valor de la procalcitonina al ingreso en terapia intensiva para el diagnóstico y el pronóstico de la sepsis. Med Intensiva. 2013, 37:156-162.
22. Tschaikowsky K., Hedwig-Geissing M., Braun G.G., Raspediel-Troeger M. Predictive value of procalcitonin, interleukin-6, and C-reactive protein for survival in postoperative patients with severe sepsis. J Crit Care. 2011, 26:54-64.
23. Miguel-Bayarri V., Casanoves-Laparra E.B., Pallás-Beneyto L., Sancho-Chinesta S., Martín Osorio L.F., Tormo-Caladín C., et al. Valor pronóstico de los biomarcadores procalcitonina, interleukina 6 y proteína C reactiva en la sepsis grave. Med Intensiva. 2012, 36:556-562.
24. Claeys R., Vinken S., Spapen H., ver Elst K., Decochez K., Huyghens L., et al. Plasma procalcitonin and C-reactive protein in acute shock septic: Clinical and biological correlates. Crit Care Med. 2002, 30:757-762.
25. Ruiz-Rodríguez J.C., Caballero J., Ruiz-Sanmartín A., Ribas V.J., Pérez M., Bóveda J.L., et al. Ussefulness of procalcitonin clearance as a prognostic biomarker in septic shock. A prospective pilot study. Med Intensiva. 2012, 36:475-480.
26. Suberviola B., Castellanos-Ortega A., Ruiz Ruiz A., López-Hoyos M., Santibáñez M. Hospital mortality prognostication in sepsis using the new biomarkers suPAR and proADM in a single determination on UCI admission. Intensive Care Med. 2013, 11:1945-1952.